Boehringer Ingelheim’s investigational dual GLP-1 and glucagon receptor agonist survodutide delivered significantly greater weight loss than placebo in a phase 3 trial in adults with obesity without diabetes. The study randomized 725 participants to once-weekly doses of 3.6 mg, 6.0 mg, or placebo, alongside lifestyle counseling, and reported primary outcomes at 76 weeks. Mean body-weight change was −12.2% for 3.6 mg and −13.0% for 6.0 mg, versus −5.4% with placebo. Weight reduction of at least 5% occurred in roughly 72% and 72% of the active-dose groups, compared with 46% on placebo. Gastrointestinal side effects were the most common adverse events, with higher rates in the 6.0 mg arm. No deaths were reported in the trial. The program’s registration number is NCT06066515, with funding attributed to Boehringer Ingelheim. The results position survodutide as a contender in a crowded late-stage obesity landscape, particularly given the higher-than-placebo magnitude of weight reduction over a full-year follow-up.